<DOC>
	<DOCNO>NCT01606202</DOCNO>
	<brief_summary>A study investigate effect sublingual cannabis base medicine extract neuropathic pain associate spinal cord injury .</brief_summary>
	<brief_title>A Study Cannabis Based Medicine Extracts Placebo Patients With Pain Due Spinal Cord Injury</brief_title>
	<detailed_description>This multi-centre , double-blind , randomised , placebo-controlled , parallel-group study evaluate efficacy tolerability GW-1000-02 central neuropathic pain associate spinal cord injury . Patients screen determine eligibility complete seven 21 day baseline period . Patients return centre assessment , randomisation initial dosing . Visits occur end treatment week one end study ( treatment week three ) upon withdrawal . Throughout study , patient permit take paracetamol escape analgesic relieve breakthrough pain . Patients study could elect screen open label extension study GW-1000-02 .</detailed_description>
	<mesh_term>Spinal Cord Injuries</mesh_term>
	<criteria>Gave inform consent participation study . Male Female , age 18 year . Diagnosis nonacute spinal cord injury , central neuropathic pain wholly relieve current therapy . Central neuropathic pain mean severity Numerical Rating Scale score least four last seven day baseline period . Relatively stable neurology precede six month . Stable medication regimen precede four week . Agreement , female child bear potential male partner child bearing potential , ensure effective contraception use study three month thereafter . Had use cannabinoids least precede seven day willing abstain use cannabinoids study . Clinically acceptable laboratory result Visit 2 . Ability ( investigator 's opinion ) willingness comply study requirement . Agreement UK Home Office , general practitioner , consultant appropriate , notify participation study . History schizophrenia , psychotic illness , severe personality disorder significant psychiatric disorder depression associate underlying condition . History alcohol substance abuse . Severe cardiovascular disorder , ischaemic heart disease , arrhythmia ( well control atrial fibrillation ) , poorly control hypertension severe heart failure . History autonomic dysreflexia . History epilepsy . If female , pregnant lactating , plan pregnancy occur course study . Significant renal hepatic impairment . Elective surgery procedure require general anaesthesia schedule occur study . Terminal illness consider inappropriate placebo medication . Any significant disease disorder , opinion investigator , may either put subject risk participation study , may influence result study , subject 's ability participate study . Regular levodopa therapy within seven day lead study entry . If male , receive unwilling stop sildenafil duration study . Known suspect hypersensitivity cannabinoids excipients study medication . Known suspect adverse reaction cannabinoids . Intention travel internationally study . Intention donate blood study . Participation another research study 12 week lead study entry . Previous randomisation study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2012</verification_date>
</DOC>